Ionis Releases Data from the Phase 1/2 Halos Clinical Trial

Ionis Pharmaceuticals issued a press release today regarding their Phase 1/2a HALOS clinical trial of ION582 for individuals living with Angelman syndrome.

Read the Ionis press release here.

Livestream Update on July 24

Join the livestream on July 24th at 3:10pm ET where Ionis will present information to parents and caregivers at the Angelman Syndrome Foundation (ASF) Family Conference.

Watch the Livestream here.